Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.

Authors

Celia Oreja-Guevara, Sven G Meuth, Nikos Grigoriadis, Patrick Vermersch, Hans Peter Hartung, Per Soelberg Sörensen, Letizia Leocani, Klaus Schmierer, Ralf Gold, Óscar Fernández

Published in

Frontiers in immunology. Volume 17. Pages 1832582. Epub Jun 12, 2026.

Abstract

Life expectancy and the age at onset of multiple sclerosis (MS) are increasing, and a growing proportion of people with MS (pwMS) are now older than 55-60 years. Aging modifies MS pathobiology, with the dominant disease mechanisms moving from focal, relapse-driven inflammation to chronic, compartmentalized neuroinflammation and neurodegeneration. In this narrative review, we summarize current knowledge on the relationship between brain aging and MS, integrating clinical, radiological, pathological and therapeutic evidence. We first discuss mechanisms of immunosenescence and "inflammaging", including changes in adaptive and innate immunity, gut microbiota dysbiosis, mitochondrial dysfunction and blood-brain barrier dysfunction, and how these processes favor microglial activation, slowly expanding lesions, smouldering MS and progression independent of relapse activity. We then examine the impact of age on disability trajectories, cognitive decline and comorbidities, and the role of vascular and neurodegenerative mechanisms. The review also addresses age-related changes in safety and efficacy of disease-modifying therapies (DMT), with a focus on high-efficacy DMT, de-escalation and discontinuation strategies, and the management of infections, malignancies and polypharmacy in older pwMS. Finally, we describe new approaches relevant to this population, including Bruton's tyrosine kinase inhibitors, neuroprotective and remyelinating agents, advanced cellular therapies and lifestyle-based interventions. We conclude by outlining practical implications for personalized treatment decisions in older pwMS and open questions that future clinical trials and biomarker studies must address.

PMID:
42367807
Bibliographic data and abstract were imported from PubMed on 19 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.